Urology News and Research

Latest Urology News and Research

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

Multiple medication use may increase severity of erectile dysfunction

The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International.

15 Nov 2011

Watson receives FDA approval for generic Kadian ANDA

Watson Pharmaceuticals, Inc. today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian.

11 Nov 2011

Novartis files suit against Watson over generic Exelon

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr.

11 Nov 2011

Two U-M physicians caution about implications of cardiac imaging study

Two University of Michigan Health System physicians are raising notes of caution about the implications of a new study that found cardiologists were more likely to refer patients for stress imaging when their practice owned imaging machines - resulting in potential overuse because of financial incentives.

9 Nov 2011

Second molecular conductor discovered in some children with biliary atresia

Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

9 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

Teaching hospitals might provide better radical prostatectomy results

Prostate cancer patients who undergo radical prostatectomy get better results at teaching hospitals than at non-academic medical institutions, according to the findings of an international study led by researchers at Henry Ford Hospital.

8 Nov 2011

Survey shows low awareness for non-surgical permanent birth control methods

A recent first-of-its-kind survey of 1,006 mothers in the U.S. showed that more than 75 percent of women reported being done having children, but only 24 percent discussed this decision with their OB/GYNs.

8 Nov 2011

Viewpoints: Weighing the ballot measures in Miss. and Ohio; the super committee's task

For all their sincerity and fervor, proponents of the personhood movement represent a small minority nationwide. In Gallup polls, support for a total abortion ban is almost exactly where it was in 1973 - at just over 20%, despite a rise in backing for limitations. Most people certainly don't want homicide charges brought against women who choose to have abortions or doctors who perform them.

8 Nov 2011

Bike riding cuts off blood flow to men's genitals

Is it just an urban myth, or can long-term bike riding cause sexual dysfunction in men? Previous studies have not shed much light on the question, says Dr. Craig Niederberger, professor and head of urology at the University of Illinois at Chicago College of Medicine, because they have not shown whether bike riding actually cuts off blood flow to men's genitals.

7 Nov 2011

EAU, ESTRO and ESMO to host European conference on urological cancers

The 3rd European Multidisciplinary Meeting on Urological Cancers will kick off this Friday, bringing together representatives of three adjacent fields involved in the management of prostate, bladder, kidney, testicular and penile cancer.

3 Nov 2011

FDA approves Endo Pharmaceuticals' Felodipine Extended-release Tablets

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg.

3 Nov 2011

Prostate cancer patients with bone metastases benefit from repeated 188Re-HEDP therapy

For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

2 Nov 2011

Watson third quarter net income increases 31% to $138.7 million

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.

1 Nov 2011

New method can reduce intrusive thoughts in men with prostate cancer

Men with prostate cancer are twice as likely to commit suicide, but a method where they put intrusive thoughts into words may reduce this risk, reveals research at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

1 Nov 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

Massachusetts court awards injunction preventing Watson from selling Amphastar's generic LOVENOX

Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX.

29 Oct 2011

Patients with ANCA-associated vasculitis harbor Flt1 protein that blocks blood vessel repair

In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011

Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis

On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.

22 Oct 2011